Cargando…

Impact of prophylactic administration of Levosimendan on short-term and long-term outcome in high-risk patients with severely reduced left-ventricular ejection fraction undergoing cardiac surgery – a retrospective analysis

BACKGROUND: Patients with severely reduced left-ventricular ejection fraction carry a high risk of morbidity and mortality after cardiac surgery. Levosimendan can be used prophylactically in these patients having shown positive effects on short-term outcome. However, effects on long-term outcome and...

Descripción completa

Detalles Bibliográficos
Autores principales: Grieshaber, Philippe, Lipp, Stella, Arnold, Andreas, Görlach, Gerold, Wollbrück, Matthias, Roth, Peter, Niemann, Bernd, Wilhelm, Jochen, Böning, Andreas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5131413/
https://www.ncbi.nlm.nih.gov/pubmed/27906091
http://dx.doi.org/10.1186/s13019-016-0556-2
_version_ 1782470889900605440
author Grieshaber, Philippe
Lipp, Stella
Arnold, Andreas
Görlach, Gerold
Wollbrück, Matthias
Roth, Peter
Niemann, Bernd
Wilhelm, Jochen
Böning, Andreas
author_facet Grieshaber, Philippe
Lipp, Stella
Arnold, Andreas
Görlach, Gerold
Wollbrück, Matthias
Roth, Peter
Niemann, Bernd
Wilhelm, Jochen
Böning, Andreas
author_sort Grieshaber, Philippe
collection PubMed
description BACKGROUND: Patients with severely reduced left-ventricular ejection fraction carry a high risk of morbidity and mortality after cardiac surgery. Levosimendan can be used prophylactically in these patients having shown positive effects on short-term outcome. However, effects on long-term outcome and patient subgroups benefiting the most are unknown. We aim to address these topics with real-life data from our clinical practice. METHODS: Two hundred eigthy eight patients with preoperative LVEF ≤ 35% underwent cardiac surgery with cardiopulmonary bypass between 2009 and 2013. Thereof, 246 were included in the matched analysis. Eigthy two patients received 12.5mg Levosimendan starting at induction of anesthesia. Outcomes of patients undergoing coronary artery bypass grafting surgery (n = 103), isolated valve surgery/ascending aortic surgery (n = 45) and those undergoing combination procedures (n = 98) were analyzed separately. Additionally, multivariate regression analysis was conducted in order to identify predictors of short-term outcome parameters for different subgroups of patients. RESULTS: Thirty days mortality rates of 16% in the Levosimendan group and 21% in the control group (OR 0.7; 95%–CI 0.36–1.5; p = 0.37) were observed. Levosimendan showed a positive effect on postoperative renal function. A higher rate of new-onset atrial fibrillation (OR 4.0; 95%–CI 2.2–7-2; p < 0.0001) was observed in the Levosimendan group. Follow-up until three years postoperatively showed no differences in long-term survival between the groups. CONCLUSION: Prophylactic administration of Levosimendan did not affect overall short- and long-term outcomes. The value of prophylactic use of Levosimendan remains questionable and more data is needed to confirm subgroups that might benefit most. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13019-016-0556-2) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5131413
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-51314132016-12-12 Impact of prophylactic administration of Levosimendan on short-term and long-term outcome in high-risk patients with severely reduced left-ventricular ejection fraction undergoing cardiac surgery – a retrospective analysis Grieshaber, Philippe Lipp, Stella Arnold, Andreas Görlach, Gerold Wollbrück, Matthias Roth, Peter Niemann, Bernd Wilhelm, Jochen Böning, Andreas J Cardiothorac Surg Research Article BACKGROUND: Patients with severely reduced left-ventricular ejection fraction carry a high risk of morbidity and mortality after cardiac surgery. Levosimendan can be used prophylactically in these patients having shown positive effects on short-term outcome. However, effects on long-term outcome and patient subgroups benefiting the most are unknown. We aim to address these topics with real-life data from our clinical practice. METHODS: Two hundred eigthy eight patients with preoperative LVEF ≤ 35% underwent cardiac surgery with cardiopulmonary bypass between 2009 and 2013. Thereof, 246 were included in the matched analysis. Eigthy two patients received 12.5mg Levosimendan starting at induction of anesthesia. Outcomes of patients undergoing coronary artery bypass grafting surgery (n = 103), isolated valve surgery/ascending aortic surgery (n = 45) and those undergoing combination procedures (n = 98) were analyzed separately. Additionally, multivariate regression analysis was conducted in order to identify predictors of short-term outcome parameters for different subgroups of patients. RESULTS: Thirty days mortality rates of 16% in the Levosimendan group and 21% in the control group (OR 0.7; 95%–CI 0.36–1.5; p = 0.37) were observed. Levosimendan showed a positive effect on postoperative renal function. A higher rate of new-onset atrial fibrillation (OR 4.0; 95%–CI 2.2–7-2; p < 0.0001) was observed in the Levosimendan group. Follow-up until three years postoperatively showed no differences in long-term survival between the groups. CONCLUSION: Prophylactic administration of Levosimendan did not affect overall short- and long-term outcomes. The value of prophylactic use of Levosimendan remains questionable and more data is needed to confirm subgroups that might benefit most. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13019-016-0556-2) contains supplementary material, which is available to authorized users. BioMed Central 2016-12-01 /pmc/articles/PMC5131413/ /pubmed/27906091 http://dx.doi.org/10.1186/s13019-016-0556-2 Text en © The Author(s). 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Grieshaber, Philippe
Lipp, Stella
Arnold, Andreas
Görlach, Gerold
Wollbrück, Matthias
Roth, Peter
Niemann, Bernd
Wilhelm, Jochen
Böning, Andreas
Impact of prophylactic administration of Levosimendan on short-term and long-term outcome in high-risk patients with severely reduced left-ventricular ejection fraction undergoing cardiac surgery – a retrospective analysis
title Impact of prophylactic administration of Levosimendan on short-term and long-term outcome in high-risk patients with severely reduced left-ventricular ejection fraction undergoing cardiac surgery – a retrospective analysis
title_full Impact of prophylactic administration of Levosimendan on short-term and long-term outcome in high-risk patients with severely reduced left-ventricular ejection fraction undergoing cardiac surgery – a retrospective analysis
title_fullStr Impact of prophylactic administration of Levosimendan on short-term and long-term outcome in high-risk patients with severely reduced left-ventricular ejection fraction undergoing cardiac surgery – a retrospective analysis
title_full_unstemmed Impact of prophylactic administration of Levosimendan on short-term and long-term outcome in high-risk patients with severely reduced left-ventricular ejection fraction undergoing cardiac surgery – a retrospective analysis
title_short Impact of prophylactic administration of Levosimendan on short-term and long-term outcome in high-risk patients with severely reduced left-ventricular ejection fraction undergoing cardiac surgery – a retrospective analysis
title_sort impact of prophylactic administration of levosimendan on short-term and long-term outcome in high-risk patients with severely reduced left-ventricular ejection fraction undergoing cardiac surgery – a retrospective analysis
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5131413/
https://www.ncbi.nlm.nih.gov/pubmed/27906091
http://dx.doi.org/10.1186/s13019-016-0556-2
work_keys_str_mv AT grieshaberphilippe impactofprophylacticadministrationoflevosimendanonshorttermandlongtermoutcomeinhighriskpatientswithseverelyreducedleftventricularejectionfractionundergoingcardiacsurgeryaretrospectiveanalysis
AT lippstella impactofprophylacticadministrationoflevosimendanonshorttermandlongtermoutcomeinhighriskpatientswithseverelyreducedleftventricularejectionfractionundergoingcardiacsurgeryaretrospectiveanalysis
AT arnoldandreas impactofprophylacticadministrationoflevosimendanonshorttermandlongtermoutcomeinhighriskpatientswithseverelyreducedleftventricularejectionfractionundergoingcardiacsurgeryaretrospectiveanalysis
AT gorlachgerold impactofprophylacticadministrationoflevosimendanonshorttermandlongtermoutcomeinhighriskpatientswithseverelyreducedleftventricularejectionfractionundergoingcardiacsurgeryaretrospectiveanalysis
AT wollbruckmatthias impactofprophylacticadministrationoflevosimendanonshorttermandlongtermoutcomeinhighriskpatientswithseverelyreducedleftventricularejectionfractionundergoingcardiacsurgeryaretrospectiveanalysis
AT rothpeter impactofprophylacticadministrationoflevosimendanonshorttermandlongtermoutcomeinhighriskpatientswithseverelyreducedleftventricularejectionfractionundergoingcardiacsurgeryaretrospectiveanalysis
AT niemannbernd impactofprophylacticadministrationoflevosimendanonshorttermandlongtermoutcomeinhighriskpatientswithseverelyreducedleftventricularejectionfractionundergoingcardiacsurgeryaretrospectiveanalysis
AT wilhelmjochen impactofprophylacticadministrationoflevosimendanonshorttermandlongtermoutcomeinhighriskpatientswithseverelyreducedleftventricularejectionfractionundergoingcardiacsurgeryaretrospectiveanalysis
AT boningandreas impactofprophylacticadministrationoflevosimendanonshorttermandlongtermoutcomeinhighriskpatientswithseverelyreducedleftventricularejectionfractionundergoingcardiacsurgeryaretrospectiveanalysis